X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
JAN101 is a patented sustained release form of sodium nitrite aimed at improving vascular function, reducing neuropathic pain and other conditions resulting from poor blood flow for treatment of painful diabetic peripheral neuropathy.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Neurology Product Name: JAN 101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2023
Details:
JAN101 is a patented sustained release form of sodium nitrite aimed at improving vascular function, reducing neuropathic pain and other conditions resulting from poor blood flow for treatment of painful diabetic peripheral neuropathy.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Neurology Product Name: JAN 101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
Recent studies have in fact suggested that PAD is a microvascular disease, so the observation that JAN101 (Sodium nitrite) improves microvascular and nerve function is crucial in treating this disease.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
Sale of GeoTraq, a wholly-owned subsidiary of JanOne to SPYR Technologies will help main business continue to fund the necessary clinical trials for JAN101 (TV1001SR), a slow-release formulation of sodium nitrite used for treatment for peripheral artery disease.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SPYR Technologies
Deal Size: $13.5 million Upfront Cash: $13.5 million
Deal Type: Divestment May 31, 2022
Details:
JAN101 is a patented sustained release form of sodium nitrite aimed at improving vascular function, reducing neuropathic pain and other conditions resulting from poor blood flow for treatment of Peripheral Artery Disease (PAD).
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
The primary endpoint will be the ability of patients to walk without pain or muscle fatigue as a result of vascular function restored by JAN101.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2021
Details:
JAN101 is intended to address the 8.5 million Americans who may have PAD. One of the more encouraging outcomes from patients who participated in early Phase 1 and Phase 2a trials of JAN101 was a reported reduction in associated PAD pain.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in the near future. JAN101 is highly selective, acting only in damaged tissue.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2021
Details:
The company intends to use the net proceeds from the offering for working capital and general corporate purposes, including planning of clinical trials for JAN101, the company’s lead drug candidate.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: A.G.P./Alliance Global Partners
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 02, 2021
Details:
NOviricid is the first oral NO generating drug to be clinically tested to treat African Americans with COVID-19. NOviricid offers a fast acting, Nitric Oxide therapeutic, with proven vasodilatory and anti-viral properties, targeting the effects of the novel Coronavirus.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Infections and Infectious Diseases Product Name: NOviricid
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Company Intends to Use the proceeds for advancement of its clinical candidate, JAN101, to treat peripheral artery disease (PAD) and to find non-addictive alternatives to pain.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment September 16, 2020
Details:
Working closely with selected bottling and labeling partner, Eurofins CDMO, the company is currently on track to initiate GMP production of JAN101 to support planned Phase 2b trials to treat peripheral artery disease (PAD).
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
The Partnership aims at JanOne is preparing its investigational new drug (IND) application for FDA submission for JAN101 as a potential treatment for vascular complications caused by Covid-19.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 28, 2020
Details:
Initial JAN101 engineering batch is complete. JAN101 formulation is a patented proprietary compound of sodium nitrite that has been successful in Phase 1 and Phase 2a studies to enhance the blood flow and vascular function needed to treat PAD and Covid-19 complications.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
JanOne together with its manufacturing partner, has successfully completed the formulation of JAN101, its potential treatment for Peripheral Artery Disease (PAD) expected to soon be in Phase 2b trials.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
CATO SMS will assist JanOne in expanding its current FDA authorized Investigational New Drug (IND) for JAN101, an oral, sustained release formulation of sodium nitrite, to treat vascular complications to potentially restore endothelial cell function in COVID-19 patients.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: JanOne
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 06, 2020
Details:
Sodium nitrite has demonstrated positive results on vascular conditions, such as PAD, diabetic neuropathy and even vascular decline associated with normal aging.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TV1001SR
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
Details:
The paper demonstrates key data on the synergistic effects of acidified sodium nitrite and EDTA (active ingredients of AB569) on destroying all bacteria
Lead Product(s): Sodium Nitrite,Edetate Calcium Disodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2020
Details:
JanOne’s lead drug clinical candidate TV1001SR to treat PAD and associated pain will be manufactured by CoreRX Pharma with phase 2b trials expected to begin Q4 2020.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: JanOne
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
